Financhill
Sell
34

YI Quote, Financials, Valuation and Earnings

Last price:
$7.38
Seasonality move :
-11.1%
Day range:
$7.01 - $7.70
52-week range:
$4.15 - $12.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.03x
P/B ratio:
--
Volume:
39.8K
Avg. volume:
13.4K
1-year change:
-29.42%
Market cap:
$63.6M
Revenue:
$2B
EPS (TTM):
-$6.53

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
YI
111
$546.5M -- -4.26% -- --
CASI
CASI Pharmaceuticals
$6.3M -- 57.7% -- $4.00
CCM
Concord Medical Services Holdings
-- -- -- -- --
CPHI
China Pharma Holding
-- -- -- -- --
SVA
Sinovac Biotech
-- -- -- -- --
ZLAB
Zai Lab
$125.7M -$0.43 26.27% -47.08% $55.64
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
YI
111
$7.34 -- $63.6M -- $0.00 0% 0.03x
CASI
CASI Pharmaceuticals
$1.33 $4.00 $20.6M -- $0.00 0% 0.67x
CCM
Concord Medical Services Holdings
$5.62 -- $24.4M -- $0.00 0% 0.46x
CPHI
China Pharma Holding
$1.75 -- $5.7M -- $0.00 0% 0.91x
SVA
Sinovac Biotech
$6.47 -- $464.9M -- $55.00 0% 1.49x
ZLAB
Zai Lab
$35.49 $55.64 $3.9B -- $0.00 0% 8.62x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
YI
111
-29.25% -0.182 9.61% 0.39x
CASI
CASI Pharmaceuticals
177.43% -1.402 55.26% 0.60x
CCM
Concord Medical Services Holdings
273.84% -3.052 77.28% 0.19x
CPHI
China Pharma Holding
33.34% -2.723 40.63% 0.15x
SVA
Sinovac Biotech
3.46% 0.000 12.91% 11.22x
ZLAB
Zai Lab
17.62% -0.357 4.43% 2.64x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
YI
111
$26.8M $19.9K -13.89% -21.52% 0.04% $15.5M
CASI
CASI Pharmaceuticals
$3.6M -$10.2M -161.7% -630.22% -169.12% --
CCM
Concord Medical Services Holdings
-- -- -7.49% -19.78% -- --
CPHI
China Pharma Holding
-$136.1K -$758.6K -40.78% -61.79% -66.67% -$138.8K
SVA
Sinovac Biotech
-- -- -1.02% -1.05% -- --
ZLAB
Zai Lab
$67.8M -$56.3M -29.16% -33.29% -44.37% -$65.6M

111 vs. Competitors

  • Which has Higher Returns YI or CASI?

    CASI Pharmaceuticals has a net margin of -0.5% compared to 111's net margin of -172.28%. 111's return on equity of -21.52% beat CASI Pharmaceuticals's return on equity of -630.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    YI
    111
    5.53% -$5.50 $72.5M
    CASI
    CASI Pharmaceuticals
    58% -$0.69 $10.4M
  • What do Analysts Say About YI or CASI?

    111 has a consensus price target of --, signalling upside risk potential of 718%. On the other hand CASI Pharmaceuticals has an analysts' consensus of $4.00 which suggests that it could grow by 200.68%. Given that 111 has higher upside potential than CASI Pharmaceuticals, analysts believe 111 is more attractive than CASI Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    YI
    111
    0 0 0
    CASI
    CASI Pharmaceuticals
    0 0 0
  • Is YI or CASI More Risky?

    111 has a beta of 0.442, which suggesting that the stock is 55.797% less volatile than S&P 500. In comparison CASI Pharmaceuticals has a beta of 0.530, suggesting its less volatile than the S&P 500 by 47.038%.

  • Which is a Better Dividend Stock YI or CASI?

    111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. CASI Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios YI or CASI?

    111 quarterly revenues are $485.1M, which are larger than CASI Pharmaceuticals quarterly revenues of $6.2M. 111's net income of -$2.4M is higher than CASI Pharmaceuticals's net income of -$10.8M. Notably, 111's price-to-earnings ratio is -- while CASI Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 0.67x for CASI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    YI
    111
    0.03x -- $485.1M -$2.4M
    CASI
    CASI Pharmaceuticals
    0.67x -- $6.2M -$10.8M
  • Which has Higher Returns YI or CCM?

    Concord Medical Services Holdings has a net margin of -0.5% compared to 111's net margin of --. 111's return on equity of -21.52% beat Concord Medical Services Holdings's return on equity of -19.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    YI
    111
    5.53% -$5.50 $72.5M
    CCM
    Concord Medical Services Holdings
    -- -- $727.8M
  • What do Analysts Say About YI or CCM?

    111 has a consensus price target of --, signalling upside risk potential of 718%. On the other hand Concord Medical Services Holdings has an analysts' consensus of -- which suggests that it could grow by 113.52%. Given that 111 has higher upside potential than Concord Medical Services Holdings, analysts believe 111 is more attractive than Concord Medical Services Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    YI
    111
    0 0 0
    CCM
    Concord Medical Services Holdings
    0 0 0
  • Is YI or CCM More Risky?

    111 has a beta of 0.442, which suggesting that the stock is 55.797% less volatile than S&P 500. In comparison Concord Medical Services Holdings has a beta of -0.899, suggesting its less volatile than the S&P 500 by 189.948%.

  • Which is a Better Dividend Stock YI or CCM?

    111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Concord Medical Services Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. Concord Medical Services Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios YI or CCM?

    111 quarterly revenues are $485.1M, which are larger than Concord Medical Services Holdings quarterly revenues of --. 111's net income of -$2.4M is higher than Concord Medical Services Holdings's net income of --. Notably, 111's price-to-earnings ratio is -- while Concord Medical Services Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 0.46x for Concord Medical Services Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    YI
    111
    0.03x -- $485.1M -$2.4M
    CCM
    Concord Medical Services Holdings
    0.46x -- -- --
  • Which has Higher Returns YI or CPHI?

    China Pharma Holding has a net margin of -0.5% compared to 111's net margin of -69.14%. 111's return on equity of -21.52% beat China Pharma Holding's return on equity of -61.79%.

    Company Gross Margin Earnings Per Share Invested Capital
    YI
    111
    5.53% -$5.50 $72.5M
    CPHI
    China Pharma Holding
    -11.97% -$0.24 $10.5M
  • What do Analysts Say About YI or CPHI?

    111 has a consensus price target of --, signalling upside risk potential of 718%. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that 111 has higher upside potential than China Pharma Holding, analysts believe 111 is more attractive than China Pharma Holding.

    Company Buy Ratings Hold Ratings Sell Ratings
    YI
    111
    0 0 0
    CPHI
    China Pharma Holding
    0 0 0
  • Is YI or CPHI More Risky?

    111 has a beta of 0.442, which suggesting that the stock is 55.797% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.789, suggesting its less volatile than the S&P 500 by 21.096%.

  • Which is a Better Dividend Stock YI or CPHI?

    111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios YI or CPHI?

    111 quarterly revenues are $485.1M, which are larger than China Pharma Holding quarterly revenues of $1.1M. 111's net income of -$2.4M is lower than China Pharma Holding's net income of -$785.6K. Notably, 111's price-to-earnings ratio is -- while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 0.91x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    YI
    111
    0.03x -- $485.1M -$2.4M
    CPHI
    China Pharma Holding
    0.91x -- $1.1M -$785.6K
  • Which has Higher Returns YI or SVA?

    Sinovac Biotech has a net margin of -0.5% compared to 111's net margin of --. 111's return on equity of -21.52% beat Sinovac Biotech's return on equity of -1.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    YI
    111
    5.53% -$5.50 $72.5M
    SVA
    Sinovac Biotech
    -- -- $11.8B
  • What do Analysts Say About YI or SVA?

    111 has a consensus price target of --, signalling upside risk potential of 718%. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that 111 has higher upside potential than Sinovac Biotech, analysts believe 111 is more attractive than Sinovac Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    YI
    111
    0 0 0
    SVA
    Sinovac Biotech
    0 0 0
  • Is YI or SVA More Risky?

    111 has a beta of 0.442, which suggesting that the stock is 55.797% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock YI or SVA?

    111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. 111 pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

  • Which has Better Financial Ratios YI or SVA?

    111 quarterly revenues are $485.1M, which are larger than Sinovac Biotech quarterly revenues of --. 111's net income of -$2.4M is higher than Sinovac Biotech's net income of --. Notably, 111's price-to-earnings ratio is -- while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 1.49x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    YI
    111
    0.03x -- $485.1M -$2.4M
    SVA
    Sinovac Biotech
    1.49x -- -- --
  • Which has Higher Returns YI or ZLAB?

    Zai Lab has a net margin of -0.5% compared to 111's net margin of -45.49%. 111's return on equity of -21.52% beat Zai Lab's return on equity of -33.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    YI
    111
    5.53% -$5.50 $72.5M
    ZLAB
    Zai Lab
    63.71% -$0.40 $984.2M
  • What do Analysts Say About YI or ZLAB?

    111 has a consensus price target of --, signalling upside risk potential of 718%. On the other hand Zai Lab has an analysts' consensus of $55.64 which suggests that it could grow by 56.77%. Given that 111 has higher upside potential than Zai Lab, analysts believe 111 is more attractive than Zai Lab.

    Company Buy Ratings Hold Ratings Sell Ratings
    YI
    111
    0 0 0
    ZLAB
    Zai Lab
    7 1 0
  • Is YI or ZLAB More Risky?

    111 has a beta of 0.442, which suggesting that the stock is 55.797% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.125%.

  • Which is a Better Dividend Stock YI or ZLAB?

    111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios YI or ZLAB?

    111 quarterly revenues are $485.1M, which are larger than Zai Lab quarterly revenues of $106.5M. 111's net income of -$2.4M is higher than Zai Lab's net income of -$48.4M. Notably, 111's price-to-earnings ratio is -- while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 8.62x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    YI
    111
    0.03x -- $485.1M -$2.4M
    ZLAB
    Zai Lab
    8.62x -- $106.5M -$48.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
92
BGL alert for Jul 3

Blue Gold [BGL] is down 17.29% over the past day.

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 0.03% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is up 0.91% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock